HomeCoronary diseaseDrug-eluting stents

Drug-eluting stents

Ver Categoría

Coronary disease

Everolimus -eluting stent to 3 years, most security was the key difference.

Original title: Everolimus-eluting stents in patients undergoing percutaneous coronary Intervention: Final 3-year results of the Clinical Evaluation of...
solaci -
Ver más
Coronary disease

Similar results of drug-eluting stents with biodegradable polymer versus permanent

Original title: Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting StentA Randomized, Controlled, Noninferiority Trial.NEXT trial. Reference: Masahiro Natsuaki et...
solaci -
Ver más
Antithrombotic Anticoagulants

Cilostazol reduces restenosis of DES in lesions larger than 40 mm.

Original title: Comparison of Dual Versus Triple Antiplatelet Therapy After Drug-Eluting Stent According to Stent Length (from the...
solaci -
Ver más
Coronary disease

Paclitaxel eluting balloon . More effective in restenosis of BMS than DES

Original title: A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal...
solaci -
Ver más
Coronary disease

Everolimus Eluting Stent in multiple vessels with short SYNTAX score

Original title: A Clinical and Angiographic Study of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment...
solaci -
Ver más
Coronary disease

2nd generation drug-eluting stents intended for left main coronary artery

Original title: Zotarolimus- versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. ISAR-LEFT MAIN 2 Study. Reference: Julinda Mehilli...
solaci -
Ver más
Coronary disease

Zotarolimus-eluting stent in-stent restenosis

Original title: Clinical Outcomes of the Resolute Zotarolimus-Eluting Stent in Patients With In-Stent Restenosis Two-Year Results From a...
solaci -
Ver más
Coronary disease

Pharmacological stent intimal coverage with overlap versus no overlap

Original title: Tissue coverage and neointimal hyperplasia in overlap versus nonoverlap segments of drug-eluting stents 9 to 13...
solaci -
Ver más